Copper-64 trastuzumab PET imaging: a reproducibility study
- 12 May 2016
- journal article
- research article
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 63 (2) , 191-+
Abstract
The current study aims to assess the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging with copper-64 (64Cu) trastuzumab. An IV injection of 296-370 MBq/5 mg 64Cu-trastuzumab was administered between 1 to 4 hours after routine trastuzumab treatment. Whole-body PET scans were performed immediately post-injection and at 24 hours post-injection. Serial pharmacokinetics were performed. Of 11 patients (median age of 52; range of 31-61), 8 underwent a repeat study with 64Cu-trastuzumab to assess image and pharmacokinetic reproducibility. Patients were monitored for toxicity. Patients experienced no allergic reactions or significant adverse effects from 64Cu-trastuzumab. Eight patients successfully completed a repeat 64Cu-trastuzumab study, with acceptable reproducibility of both the biodistribution and pharmacokinetic clearance. Study 1 versus study 2 showed similar serum concentration post-injection (mean 42.4±7.8 %ID/L vs. 44.7±12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 hours), P>0.5. The volume of distribution (median 2.50 L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60 L. Of 11 patients, two had 64Cu-trastuzumab localization corresponding to known tumor sites - one in liver and one in breast. Preliminary results suggest that scanning with 64Cu-trastuzumab is feasible, safe, and reproducible. Tumor uptake of 64Cu-trastuzumab was observed, but tumor detection exhibited low sensitivity in this study in which imaging was performed in the presence of trastuzumab therapy.Keywords
This publication has 30 references indexed in Scilit:
- Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancerNuclear Medicine Communications, 2013
- 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PETJournal of Nuclear Medicine, 2011
- 124I-huA33 Antibody PET of Colorectal CancerJournal of Nuclear Medicine, 2011
- HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysisBreast Cancer Research and Treatment, 2011
- 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In VivoJournal of Nuclear Medicine, 2010
- 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograftEuropean Journal of Cancer, 2010
- Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-TrastuzumabPLOS ONE, 2010
- 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicityEuropean Journal of Cancer, 2007
- Efficient production of high specific activity 64Cu using a biomedical cyclotronNuclear Medicine and Biology, 1997
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987